Revvity (NYSE:RVTY) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Revvity (NYSE:RVTY) released its quarterly earnings results on Tuesday. The company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04, FiscalAI reports. Revvity had a return on equity of 7.92% and a net margin of 8.45%.The firm had revenue of $711.12 million during the quarter, compared to analysts’ expectations of $704.20 million. During the same quarter in the prior year, the business earned $1.01 EPS. Revvity’s quarterly revenue was up 7.0% compared to the same quarter last year. Revvity updated its FY 2026 guidance to 5.200-5.300 EPS.

Here are the key takeaways from Revvity’s conference call:

• Signed a letter of intent to divest the China immunodiagnostics business (?6% of 2025 revenue), expects a definitive agreement within ~2 months and closing by end of 2027, and says the move will reweight China to ~8%–9% of revenue and boost 2026 pro forma organic growth ~100 bps and margins ~30 bps.
• Revvity beat Q1 expectations with 3% organic growth, adjusted operating margin of 23.6% and adjusted EPS of $1.06; excluding the China immunodiagnostics business, Q1 pro forma results would have been ~6% organic growth and a 24% pro forma margin.
• Software and AI are core growth drivers: the company launched Xynthetica, BioDesign, and LabGistics this year, reports SaaS/ARR growth north of 30%–40% year?over?year and says internal AI deployment (cited by Gartner) is accelerating product delivery and employee productivity.
• Balance sheet and cash generation remain strong — Q1 free cash flow was $115M (?97% conversion of adjusted net income), the company repurchased $86M of stock in the quarter, finished with net leverage ~2.8x and plans to repay a ~€600M bond in July.
• Near?term financial impact: management lowered reported 2026 adjusted EPS by roughly $0.15 to a pro forma range of $5.20–$5.30 (the guide excludes any sale proceeds), and the planned divestiture reduces previously expected 2026 revenue by ~4.5%, creating short?term dilution and timing uncertainty until closing.

Revvity Stock Performance

Shares of Revvity stock opened at $88.71 on Tuesday. The firm has a market cap of $9.92 billion, a PE ratio of 42.65, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05. The firm’s 50-day simple moving average is $90.39 and its 200-day simple moving average is $96.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.40 and a current ratio of 1.68. Revvity has a 1 year low of $81.22 and a 1 year high of $118.30.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Stockholders of record on Friday, July 17th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.3%. Revvity’s payout ratio is presently 13.46%.

Key Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 results beat expectations — EPS $1.06 vs. $1.02 estimate and revenue of $711.1M (up 7% y/y), demonstrating near-term operational strength. Revvity (RVTY) Q1 Earnings and Revenues Top Estimates
• Neutral Sentiment: The company provided supplemental materials and a conference call for details (slides and press release available), which will drive near-term investor attention as markets digest the guidance details. View Press Release
• Neutral Sentiment: An analyst note lowered Revvity’s price target (Robert W. Baird cut to $125 but kept an outperform rating), a mixed signal—less optimism on upside but continued conviction on longer-term growth. Price Target Cut to $125.00 by Analysts at Robert W. Baird
• Neutral Sentiment: Brokerage consensus sits around a “Hold,” indicating analysts are cautious until the company’s FY guidance and end-market trends (notably China and academic demand) clarify. Revvity Inc. Given Average Recommendation of “Hold” by Brokerages
• Negative Sentiment: FY2026 guidance disappointed: EPS guidance of $5.20–$5.30 vs. ~5.40 consensus and revenue guidance near $2.8B (below the ~$3.0B expectation) — the main driver of the stock decline as it reduces near-term upside for estimates. Revvity to Report Q1 Earnings: What’s in Store for the Stock?

Wall Street Analysts Forecast Growth

RVTY has been the topic of a number of recent research reports. TD Cowen reissued a “hold” rating on shares of Revvity in a research report on Tuesday, February 3rd. Wells Fargo & Company raised their price target on shares of Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a report on Tuesday, February 3rd. Weiss Ratings downgraded shares of Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Robert W. Baird cut their price objective on shares of Revvity from $129.00 to $125.00 and set an “outperform” rating on the stock in a report on Monday. Finally, The Goldman Sachs Group decreased their price objective on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a research report on Tuesday, April 14th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $109.36.

Hedge Funds Weigh In On Revvity

Hedge funds have recently bought and sold shares of the company. Morgan Stanley increased its holdings in Revvity by 29.6% in the fourth quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock valued at $275,202,000 after buying an additional 650,083 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Revvity by 22.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company’s stock worth $252,727,000 after buying an additional 486,159 shares during the last quarter. Neuberger Berman Group LLC grew its position in shares of Revvity by 98.3% in the 4th quarter. Neuberger Berman Group LLC now owns 912,866 shares of the company’s stock worth $88,320,000 after acquiring an additional 452,419 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Revvity by 5.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after acquiring an additional 434,570 shares in the last quarter. Finally, UBS Group AG increased its holdings in shares of Revvity by 22.3% in the 3rd quarter. UBS Group AG now owns 2,179,505 shares of the company’s stock valued at $191,034,000 after acquiring an additional 397,160 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.